| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCTD17 |
| Uniprot No | Q8N5Z5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-321aa |
| 活性数据 | MQTPRPAMRM EAGEAAPPAG AGGRAAGGWG KWVRLNVGGT VFLTTRQTLC REQKSFLSRL CQGEELQSDR DETGAYLIDR DPTYFGPILN FLRHGKLVLD KDMAEEGVLE EAEFYNIGPL IRIIKDRMEE KDYTVTQVPP KHVYRVLQCQ EEELTQMVST MSDGWRFEQL VNIGSSYNYG SEDQAEFLCV VSKELHSTPN GLSSESSRKT KSTEEQLEEQ QQQEEEVEEV EVEQVQVEAD AQEKAQSSQD PANLFSLPPL PPPPLPAGGS RPHPLRPEAE LAVRASPRPL ARPQSCHPCC YKPEAPGCEA PDHLQGLGVP I |
| 分子量 | 34.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人KCTD17蛋白的3篇参考文献的示例(内容基于领域研究背景综合，部分信息可能需要根据实际文献调整)：
---
1. **文献名称**: *KCTD17 is a regulator of ubiquitin-dependent signaling and ciliogenesis*
**作者**: Suzuki T, et al.
**摘要**: 本研究揭示了重组人KCTD17蛋白通过调控Cullin3泛素连接酶复合物活性，影响纤毛形成和Hedgehog信号通路。实验证明KCTD17在体外与Cullin3直接结合，并调节其稳定性，可能与神经发育疾病相关。
2. **文献名称**: *Structural and functional analysis of the potassium channel tetramerization domain-containing protein 17 (KCTD17)*
**作者**: Zhang Y, et al.
**摘要**: 通过X射线晶体学解析重组人KCTD17蛋白的BTB结构域三维结构，发现其参与蛋白寡聚化及与其他E3泛素连接酶组分的相互作用，为研究KCTD家族在蛋白质降解中的作用提供结构基础。
3. **文献名称**: *KCTD17 mutations in Parkinson's disease: implications for proteasomal dysfunction*
**作者**: Mariani LL, et al.
**摘要**: 研究通过重组KCTD17蛋白验证了其在帕金森病相关突变体(如R134Q)中的功能缺失，发现突变导致与Cullin3的结合能力下降，进而影响泛素-蛋白酶体系统，提示KCTD17在神经退行性疾病中的病理机制。
---
**说明**：以上为基于KCTD蛋白家族研究背景的示例文献。实际文献需通过PubMed、Google Scholar等平台用关键词“recombinant KCTD17”或“KCTD17 function”检索。建议结合具体研究方向筛选近年高影响力论文。
Recombinant human KCTD17 protein is a genetically engineered variant of the potassium channel tetramerization domain-containing protein 17 (KCTD17), a member of the KCTD family implicated in diverse cellular processes. KCTD17 contains a conserved BTB/POZ domain, facilitating protein-protein interactions, and a unique C-terminal region. It functions as a substrate adaptor for Cullin3 (Cul3)-based ubiquitin ligase complexes, regulating protein ubiquitination and degradation. Studies link KCTD17 to neurological disorders, including epilepsy and spinocerebellar ataxia, through its interaction with cytoskeletal proteins and synaptic regulators. It also modulates Hedgehog and mTOR signaling pathways, suggesting roles in development and cancer.
Recombinant KCTD17 is typically produced in bacterial or mammalian expression systems, enabling structural and functional studies. Its solubility and stability vary depending on post-translational modifications, which may influence binding partners like Cul3 or HSP70. Research leverages recombinant protein to dissect molecular mechanisms underlying KCTD17-associated pathologies. For instance, mutations disrupting its Cul3 interaction impair ubiquitination activity, contributing to disease pathogenesis. In cancer, aberrant KCTD17 expression correlates with tumor progression, spurring interest in its therapeutic potential. Current challenges include resolving its full interactome and disease-specific conformational changes. As a tool, recombinant KCTD17 aids in screening small molecules targeting KCTD family proteins, offering avenues for drug development.
×
